Meeting
2021 Genitourinary Cancers Symposium
Rucaparib plus enzalutamide in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Pharmacokinetics (PK) and safety data from the phase Ib RAMP study.
Authors
Arpit Rao
University of Minnesota, Minneapolis, MN
Arpit Rao , David Morris , Vasily J. Assikis , Gautam Gopalji Jha , Charles J. Ryan , Adriel-John Ablaza , Jenn Habeck , Andrea Loehr , Jim Xiao , Esha A. Gangolli
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Prostate Cancer - Advanced Disease
Track
Prostate Cancer - Advanced
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04179396
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 79)
DOI
10.1200/JCO.2021.39.6_suppl.79
Abstract #
79
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
CheckMate 9KD cohort A1 final analysis: Nivolumab (NIVO) + rucaparib for post-chemotherapy (CT) metastatic castration-resistant prostate cancer (mCRPC).
First Author: Russell Kent Pachynski
Poster
2017 ASCO Annual Meeting
Phase 1b/2 keynote-365 trial: Pembrolizumab (pembro) combination therapy in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Evan Y. Yu
Poster
2024 ASCO Genitourinary Cancers Symposium
Anti-tumor activity of RP12146, a PARP1/2 inhibitor, in patients with metastatic castration-resistant prostate cancer.
First Author: Piotr Jan Wysocki
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase 2 expansion study of ARV-766, a PROTAC androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Daniel P. Petrylak